The company said revenue for Q2 2024 rose mainly due to higher sales volume of disposable sensors, and that the decline in gross profit margin was mainly driven by product and channel mix changes.

1. 01

   The company said revenue for Q2 2024 rose mainly due to higher sales volume of disposable sensors, and that the decline in gross profit margin was mainly driven by product and channel mix changes.

2. 02

   Dexcom cited higher compensation costs of $7.3 million and clinical trial costs of $3.0 million as drivers of the increase in research and development expense for Q2 2024, and advertising and marketing costs of $15.5 million among the drivers of higher selling, general and administrative expense.

3. 03

   The company said it had cash, cash equivalents and short-term marketable securities of $3.12 billion as of June 30, 2024, and that net cash provided by operating activities for the first half of 2024 (6 months) was $488.6 million.

4. 04

   The company said it holds senior convertible notes maturing in November 2025 and May 2028, and that as of June 30, 2024 it had no outstanding borrowings under its revolving credit facility, with $192.4 million available.

Key figures

Quarter ended June 30, 2024

Revenue

$1.0B

Operating income

$158M

Net income

$144M

EPS

$0.35

Gross profit

$627M

Analysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.